Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector

Gene Therapy

Volumn 14, Issue 23, 2007, Pages 1623-1631

  Laurie, K L ^a   Blundell, M P ^a   Baxendale, H E ^a   Howe, S J ^a   Sinclair, J ^a   Qasim, W ^a   Brunsberg, U ^b   Thrasher, A J ^a,c   Holmdahl, R ^b   Gustafsson, K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CELL PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; GLYCOPROTEIN P 15095; GR1 ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW; BONE MARROW CELL; CANCER CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; IRRADIATION; LYMPHOID TISSUE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; B-LYMPHOCYTES; CELL LINE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; IMMUNOGLOBULINS; MALE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; TRANSGENES;

CYTOMEGALOVIRUS; LENTIVIRUS; MURINAE; MUS; SPLEEN FOCUS-FORMING VIRUS;

EID: 36348946277     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303021     Document Type: Article

References (37)

1. Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005; 5: 880-892.
2. Gaspar HB, Howe S, Thrasher AJ. Gene therapy progress and prospects: gene therapy for severe combined immunodeficiency. Gene Therapy 2003; 10: 1999-2004.
3. Larsen SR, Rasko JE. Lymphoproliferative disorders: Prospects for gene therapy. Pathology 2005; 37: 523-533.
4. Melo ME, El Amine M, Tonnetti L, Fleischman L, Scott DW. Gene therapeutic approaches to induction and maintenance of tolerance. Int Rev Immunol 2001; 20: 627-645.
5. Wong W, Wood KJ. Transplantation tolerance by donor MHC gene transfer. Curr Gene Ther 2004; 4: 329-336.
6. Laddy DJ, Weiner DB. From plasmids to protection: A review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25 99-123.
7. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
8. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902-913.
9. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann NY Acad Sci 2005; 1054: 308-316.
10. Pawhuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-2371.
11. Indraccole S, Minuzzo S, Roccaforte F, Zamarchi R, Habeler W, Stievano L et al. Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood 2001; 98 3607-3617.
12. Marodon G, Mouly E, Blair EJ, Frisen C, Lemoine FM, Klatzmann D. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 2003; 101: 3416-3423.
13. Cui Y, Golob J, Kelleher E, Ye Z, Pardoll D, Cheng L. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399-408.
14. Lutzko C, Senadheera D, Skelton D, Petersen D, Kohn DB. Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes. J Virol 2003; 77: 7341-7351.
15. Werner M, Kraunus J, Baum C, Brocker T. B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element. Gene Therapy 2004; 11: 992-1000.
16. Moreau T, Bardin F, Imbert J, Chabannon C, Tonnelle C. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol Ther 2004; 10: 45-56.
17. Kalberer CP, Reininger L, Melchers F, Rolink AG. Priming of helper T cell-dependent antibody responses by hemagglutinin-transgenic B cells. Eur J Immunol 1997; 27: 2400-2407.
18. Blankenstein T, Winter E, Muller W. A retroviral expression vector containing murine immunoglobulin heavy chain promoter/enhancer. Nucleic Acids Res 1988; 16: 10939.
19. Bergman Y, Rice D, Grosschedl R, Baltimore D. Two regulatory elements for immunoglobulin kappa light chain gene expression. Proc Natl Acad Sci USA 1984; 81: 7041-7045.
20. Pettersson S, Cook GP, Bruggemann M, Williams GT, Neuberger MS. A second B cell-specific enhancer 3′ of the immunoglobulin heavy-chain locus. Nature 1990; 344: 165-168.
21. Cook GP, Meyer KB, Neuberger MS, Pettersson S. Regulated activity of the IgH intron enhancer (E mu) in the T lymphocyte lineage. Int Immunol 1995; 7: 89-95.
22. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
23. Janssens W, Chuah MK, Naldini L, Follenzi A, Collen D, Saint-Remy JM et al. Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Ther 2003; 14: 263-276.
24. Rossi GR, Mautino MR, Morgan RA. High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes. Hum Gene Ther 2003; 14: 385-391.
25. Warncke M, Vogt B, Ulrich J, von Laer MD, Beyer W, Klump H et al. Efficient in vitro transduction of naive murine B cells with lentiviral vectors. Biochem Biophys Res Commun 2004; 318: 673-679.
26. Cooper MD. Pre-B cells; normal and abnormal development. J Clin Immunol 1981; 1: 81-89.
27. Chinnasamy D, Chinnasamy N, Enriquez MJ, Otsu M, Morgan RA, Candotti F. Lentiviral-mediated gene transfer into human lymphocytes: Role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.
28. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288; 669-672.
29. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-finked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
30. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol, 1979; 122: 549-554.
31. Aaronson SA, Todaro GJ. Development of 3T3-like lines from Balb-c mouse embryo cultures: Transformation susceptibility to SV40. J Cell Physiol 1968; 72: 141-148.
32. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kihlberg J et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998; 28: 2580-2590.
33. Williams RL, Courtneidge SA, Wagner EF. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 1988; 52: 121-131.
34. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
35. Neil S, Martin F, Ikeda Y, Collins M. Postentry restriction to human immunodeficiency virus based vector transduction in human monocytes. J Virol 2001; 75: 5448-5456.
36. Laurie KL, van Driel IR, Zwar TD, Barrett SP, Gleeson PA. Endogenous H/K ATPase beta-subunit promotes T cell tolerance to the immunodominant gastritogenic determinant. J Immunol 2002; 169: 2361-2367.
37. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Therapy 2005; 12: 597-606.